BB Biotech AG
XETRA: BBZA.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Koller
- Employees
- 10
- Headquarters
- Kusnacht, Switzerland
- IPO year
- 2020
- Market cap
- €2.7B
- Website
- https://www.bbbiotech.ch/en/bb-biotech
Loading BBZA…
Loading profile data…Frequently asked questions about BBZA
What does BB Biotech AG (BBZA.DE) do?
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotec...
Where does BBZA.DE trade?
BB Biotech AG (BBZA.DE) trades on the Deutsche Börse.
What sector is BBZA.DE in?
BB Biotech AG (BBZA.DE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BB Biotech AG?
Daniel Koller is the chief executive officer of BB Biotech AG (BBZA.DE).
Where is BB Biotech AG headquartered?
BB Biotech AG is headquartered in Switzerland.
Does BBZA.DE pay a dividend?
Yes — BB Biotech AG (BBZA.DE) paid a trailing twelve-month dividend of EUR 2.47 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did BBZA.DE go public?
BB Biotech AG (BBZA.DE) completed its initial public offering in 2020.